Rochester General Hospital, an affiliate of Rochester Regional Health System, is the first in the area to use the Lutonix Drug Coated Balloon Catheter to treat Peripheral Artery Disease (PAD).
PAD is a life-threatening condition that affects millions of Americans by narrowing arteries and reducing blood flow to the limbs. Worldwide it is estimates that 200 million people suffer from PAD.
“Minimally-invasive endovascular procedures such as angioplasty balloons and stents, medications and vascular bypass surgery are some of the accepted ways to treat PAD,” said Jeffrey Rhodes MD, a Vascular Surgeon at Rochester General. “What makes the Lutonix Catheter unique is the drug coating, which is designed to prevent scaring once the arteries are opened by the balloon catheter.”
Left untreated, Peripheral Artery Disease (PAD) can result in the loss of limbs. In fact, PAD is the leading cause of amputation in people over the age of 50 and accounts for up to 90% of amputations overall.
For more information on this latest technology and how it may benefit you or a loved one, please call Vascular Surgery Associates at 922-5550.
Monday, November 5, 2018
The College of Healthcare Information Management Executives (CHIME) has named Rochester Regional Health one of Healthcare’s Most Wired for 2018. The distinction is based on the system’s ability to adopt, implement and apply new information technology to improve healthcare outcomes.Read News Article
Friday, October 26, 2018
Meet Nicole Snyder: a mother, a wife, and a breast cancer survivor. Her diligence about routine breast screening may have saved her life.Read News Article